PYLARIFY PET/CT Case Studies
In 2 patients with similar clinical presentation, PYLARIFY® PET/CT reveals each patient's unique extent of disease1
In CONDOR, across the 3 readers, PYLARIFY® detected at least 1 previously occult lesion in 59.6%-65.9% of patients2,3
- 71-year-old patient had a Gleason score of 4+3, history of radical prostatectomy, EBRT with PSA 1.92 ng/mL, and equivocal results on 18F fluciclovine PET/CT scan
- PYLARIFY® showed left common iliac lesions and multiple retroperitoneal para/peri aortic lymph node lesions
- Biopsy of retroperitoneal lymph node confirmed prostate cancer
ADT=androgen deprivation therapy; BCR=biochemical recurrence; CT=computed tomography; EBRT=external beam radiation therapy; IMRT=intensity-modulated radiation therapy; MIP=maximum intensity projection; MRI=magnetic resonance imaging; PCa=prostate cancer; PET=positron emission tomography; PSA=prostate-specific antigen; SBRT=stereotactic body radiation therapy.
INDICATION & IMPORTANT
SAFETY INFORMATION
PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:
- with suspected metastasis who are candidates for initial definitive therapy.
- with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
Radiation Risks
Diagnostic radiopharmaceuticals, including PYLARIFY, expose patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.
INDICATION
PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:
- with suspected metastasis who are candidates for initial definitive therapy.
- with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
References
- Data on file. Bedford, MA: Progenics Pharmaceuticals, Inc.; 2023.
- Pienta KJ, Gorin MA, Rowe SP, et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J Urol. 2021;206(1):52-61. doi:10.1097/JU.0000000000001698
- Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021;27(13):3674-3682. doi:10.1158/1078-0432.CCR-20-4573